Flow cytometry-based enumeration and functional characterization of cd8 t regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 4, 2014, Pages 220-228

  Muthu Raja, Karthick Raja ^a   Plasil, Martin ^a   Rihova, Lucie ^a   Pelcova, Jana ^b   Adam, Zdenek ^b   Hajek, Roman ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

CD8 T regulatory cells; dexamethasone; flow cytometry and CFSE; immune suppression; lenalidomide; multiple myeloma

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 10; LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COHORT ANALYSIS; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DEXAMETHASONE; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84902545200     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21109     Document Type: Article

References (29)

1. Pratt G, Goodyear O, Moss P,. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563-579. (Pubitemid 47208476)
2. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, Oken MM, Kyle RA,. Blood levels of immune cells predict survival in myeloma patients: Results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 23-28.
3. Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, Bone N, Oken MM,. Circulating blood B cells in multiple myeloma: Analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood 1997; 90: 340-345. (Pubitemid 27276579)
4. Kyle RA, Rajkumar SV,. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
5. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL,. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940-3949. (Pubitemid 43726800)
6. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, Owen RG, Selby PJ, Cook G,. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009; 144: 686-695.
7. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM,. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR?/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72: 540-547.
8. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R,. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PloS one 2012; 7: e47077.
9. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A,. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: Detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012; 106: 546-552.
10. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF,. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007; 13: 6947-6958. (Pubitemid 350276874)
11. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J,. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009; 58: 520-529.
12. Li J, Huang ZF, Xiong G, Mo HY, Qiu F, Mai HQ, Chen QY, He J, Chen SP, Zheng LM, et al. Distribution, characterization, and induction of CD8(+) regulatory T cells and IL-17-producing CD8(+) T cells in nasopharyngeal carcinoma. J Translational Med 2011; 9.
13. Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, Pour L, Hajek R,. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: A cause for immune impairment. PloS one 2012; 7: e49446.
14. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V, Romagnani P, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003; 102: 4107-4114. (Pubitemid 37486995)
15. Tang XL, Smith TR, Kumar V,. Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol 2005; 2: 11-19.
16. Endharti AT, Rifa'I M, Shi Z, Fukuoka Y, Nakahara Y, Kawamoto Y, Takeda K, Isobe K, Suzuki H,. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol 2005; 175: 7093-7097. (Pubitemid 41713400)
17. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, Lederman S, Colonna M, Cortesini R, Dalla-Favera R, et al. Tolerization of dendritic cells by T(S) cells: The crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3: 237-243. (Pubitemid 34218114)
18. Xystrakis E, Dejean AS, Bernard I, Druet P, Liblau R, Gonzalez-Dunia D, Saoudi A,. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 2004; 104: 3294-3301. (Pubitemid 39507148)
19. Palumbo A, Rajkumar SV,. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449-456.
20. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM,. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32.
21. Muthu Raja KR, Kovarova L, Hajek R,. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leukemia lymphoma 2012; 53: 1406-1408.
22. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM,. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009; 23: 605-607.
23. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS,. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117: 1605-1613.
24. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155-167.
25. Kruisbeek AM, Shevach E, Thornton AM,. Proliferative assays for T cell function. In:, Coligan JE, et al., editors. Current protocols in immunology. 2004;Chapter 3:Unit 3. 12.
26. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: A comparative analysis of 411 patients. Blood 2010; 115: 1343-1350.
27. Hsu A, Ritchie DS, Neeson P,. Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone? Oncoimmunology 2012; 1: 372-374.
28. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncology 2010; 11: 29-37.
29. Raja KRM, Rihova L, Hajek R,. Evaluation of immune suppression in multiple myeloma patients treated with lenalidomide plus prednisone and lenalidomide alone. ASH Annual Meeting Abstracts 2012; 120: 3969.